Therefore, we used Glioblastoma IDH wildtype 4 patient-derived glioma stem-like cells and commercial adherent cells with a varied MGMT promoter methylation status to evaluate PU-H71’s activity against glioma cell proliferation. Here, MGMT is linked to central nervous system cancer.